This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
TCRR Aperçu des actions
TCR2 Therapeutics Inc., a clinical-stage cell therapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer.
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 0/6 |
| Performances passées | 0/6 |
| Santé financière | 4/6 |
| Dividendes | 0/6 |
TCR2 Therapeutics Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$1.48 |
| Plus haut sur 52 semaines | US$3.88 |
| Plus bas sur 52 semaines | US$0.82 |
| Bêta | 1.93 |
| 1Variation sur 1 mois | -21.28% |
| Variation sur 3 mois | 22.31% |
| Variation sur 1 an | -38.59% |
| 3Variation sur 3 ans | -88.47% |
| Variation sur 5 ans | n/a |
| Évolution depuis l'introduction en bourse | -90.18% |
Nouvelles et mises à jour récentes
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Rendement pour les actionnaires
| TCRR | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -6.3% | 0.6% | 0.8% |
| 1Y | -38.6% | 27.4% | 38.4% |
Rendement vs Industrie: TCRR underperformed the US Biotechs industry which returned 12.2% over the past year.
Rendement vs marché: TCRR underperformed the US Market which returned 2.4% over the past year.
Volatilité des prix
| TCRR volatility | |
|---|---|
| TCRR Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Cours de l'action stable: TCRR's share price has been volatile over the past 3 months.
Volatilité au fil du temps: TCRR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2015 | 58 | Garry Menzel | www.tcr2.com |
TCR2 Therapeutics Inc. Résumé des fondamentaux
| TCRR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$58.11m |
| Bénéfices(TTM) | -US$163.10m |
| Recettes(TTM) | n/a |
0.0x
Ratio P/S-0.4x
Ratio P/ELe site TCRR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| TCRR compte de résultat (TTM) | |
|---|---|
| Recettes | US$0 |
| Coût des recettes | US$0 |
| Marge brute | US$0 |
| Autres dépenses | US$163.10m |
| Les revenus | -US$163.10m |
Derniers bénéfices déclarés
Mar 31, 2023
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -4.15 |
| Marge brute | 0.00% |
| Marge bénéficiaire nette | 0.00% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de TCRR?
Voir les performances historiques et les comparaisons